State Bills To Regulate Biosimilar Substitutions Make Headway
Seventeen states are considering legislation to set rules for biosimilar substitutions, including alerting the prescribing physician and keeping long-term records of the substitutions – steps that go beyond those in place for small-molecule generic drug substitutions.
You may also be interested in...
IMS Health official says the biologic and biosimilar markets are looming growth areas as small-molecule opportunities decline, but questions about the abbreviated biosimilar pathway linger.
Absent guidance, the company says it is submitting proposals for trial designs it believes could demonstrate biosimilar interchangeability.
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.